Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia.

Pflügers Archiv : European journal of physiology
L TualJ-P Richalet

Abstract

Right ventricular hypertrophy induced by chronic hypoxia is mainly due to a mechanical stress upon the ventricular wall secondary to pulmonary arterial hypertension. However, the hypoxic chronic activation of the sympathetic nervous system can contribute to the development of right ventricular hypertrophy either via myocardial adrenergic receptors and/or a vasoconstriction and remodeling of pulmonary arteries. To highlight the specific role of the sympathetic nervous system on hypoxia-induced right ventricular hypertrophy and particularly the efficiency of carvedilol, our study compared physiological, myocardial, and pulmonary arterial morphometric data in rats treated by alpha-(prazosin), or beta-(propranolol) or alphabeta-(carvedilol) antagonist and exposed to chronic hypobaric hypoxia (2 weeks at 380 mmHg barometric pressure). In chronic hypoxia, both systolic right ventricular pressure and Fulton's ratio (right/(left+septum) ventricular weight) were lower in rats treated by prazosin (-16.7 and -13.6%), propranolol (-28.6 and -12.7%) and carvedilol (-15.9 and -14.3%) respectively when compared to glucose (p<0.05). Surprisingly, prazosin was unable to reduce right ventricular hypertrophy induced by chronic hypoxia, whereas, l...Continue Reading

References

Oct 1, 1992·Journal of Applied Physiology·R KacimiB Crozatier
Aug 1, 1989·Journal of Applied Physiology·J P RichaletP Veyrac
May 1, 1997·Cardiovascular Research·S BrimioulleR Naeije
Aug 26, 1998·Progress in Cardiovascular Diseases·G FeuersteinR R Ruffolo
Apr 20, 1999·The Journal of Clinical Investigation·S F YetM E Lee
Jul 18, 2000·Journal of the American College of Cardiology·S WeiJ E Sanderson
Feb 15, 2001·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·F FavretN C Gonzalez
Mar 14, 2001·Circulation·P H Sugden
Jan 28, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Yue-Jin YangZai-Jia Chen
Apr 26, 2003·Pflügers Archiv : European journal of physiology·Olivier-Eric MorelJean-Paul Richalet
Jul 2, 2003·Journal of Applied Physiology·Fabrice FavretNorberto C Gonzalez
Sep 23, 2003·Cardiovascular Research·Martin U BraunMathias M Borst
Jan 11, 2005·Critical Care Medicine·Alan D KayeAaron M Fields

❮ Previous
Next ❯

Citations

Jul 2, 2009·Clinical and Experimental Pharmacology & Physiology·Jun YuMiao-Zhang Zhu
May 29, 2010·American Journal of Respiratory and Critical Care Medicine·Harm J BogaardNorbert F Voelkel
Jun 5, 2012·Vascular Health and Risk Management·Gastone Leonetti, Colin G Egan
Apr 20, 2007·Respiratory Physiology & Neurobiology·B Ostadal, F Kolar
Apr 4, 2015·The Canadian Journal of Cardiology·John J RyanStephen L Archer
Apr 10, 2016·The Journal of International Medical Research·Xiaotong HanYanfei Long

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.